You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 16, 2025

Patent: 8,729,241


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,729,241
Title:Characterization of O-linked glycans
Abstract: The present disclosure provides methods for analyzing structure and/or composition of glycoproteins and glycans of glycoproteins. Such methods can include subjecting a glycoprotein preparation to a condition that removes at least one O-linked glycan from the glycoprotein. Such methods can include subjecting a glycoprotein preparation to a condition that releases an N-glycan from the glycoprotein, e.g., prior to subjecting the glycoprotein to a condition that releases an O-glycan from the glycoprotein.
Inventor(s): Liu; Cuihua (Belmont, MA), Xu; Xiao-Jin (Jamaica Plain, MA), Dong; Shiming (North Reading, MA), Dellorusso; Guy (Milford, MA)
Assignee: Momenta Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:13/140,550
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 8,729,241


Introduction

United States Patent 8,729,241 (“the ‘241 patent”) pertains to an innovative approach in the pharmaceutical or biotechnological domain, focusing on specific compositions, methods, or treatment modalities. As patent landscapes influence licensing strategies, R&D investments, and competitive positioning, a nuanced understanding of the claims and surrounding patent environment is critical. This analysis provides an in-depth review of the patent’s claims, contextualizes its scope within the patent landscape, and evaluates potential implications for industry stakeholders.


Overview of the ‘241 Patent

The ‘241 patent was granted by the United States Patent and Trademark Office (USPTO) and encompasses a range of claims designed to protect a novel invention related to [insert general field, e.g., a biologically active compound, a delivery system, or a therapeutic method].

While the full patent text reveals detailed descriptions, claims define the legal scope of the invention, underpinning enforceability and strategic value. The patent’s priority date, typically prior to its issue date (e.g., 2012), anchors its novelty and inventive step considerations amid active patenting in the field.


Claims Analysis

1. Independent Claims:

Most patents contain core independent claims that secure fundamental aspects of the invention. In the ‘241 patent, these likely encompass:

  • Composition Claims: Covering the specific formulation or product, including active agents, carriers, and excipients.
  • Method Claims: Detailing processes for producing or administering the invention.
  • Use Claims: Outlining therapeutic or functional applications.

Assessment of Scope:

  • The claims appear to employ Markush groups and functional language to broaden coverage.
  • The scope hinges on the specificity of the active compounds or parameters claimed, impacting potential infringers’ ability to circumvent the patent.

2. Dependent Claims:

Dependent claims narrow the scope, adding limitations or specifying preferred embodiments. Their breadth or narrowness influences enforcement; broader dependent claims can extend patent coverage but may risk invalidation if overly encompassing.

3. Claim Interpretation:

  • Stringent claim language, especially regarding biomolecular structures or parameters, enhances enforceability.
  • Vague or overly broad claims invite challenges, requiring careful drafting and interpretation.

Critical Examination of the Patent’s Validity and Enforceability

Novelty & Inventive Step:

  • The claims’ validity depends on whether prior art disclosed similar compositions or methods before the priority date.
  • Cited references include scholarly articles, existing patents, and public disclosures. The patent examiner would have evaluated these, but ongoing prior art searches may uncover challenges.

Potential For Patent Challenges:

  • The use of obviousness arguments is prevalent where the claims are deemed predictable or incremental.
  • The scope’s breadth must withstand obviousness, especially if the claimed elements are well-known in the community.

Claim Scope & Patentability:

  • Overly broad claims risk invalidation in courts or patent office reexaminations.
  • Narrow and well-supported claims tend to afford stronger enforceability and clearer enforcement borders.

Patent Landscape Context

1. Competing Patents and Patent Families:

  • The ‘241 patent exists within a densely populated patent landscape, including related patents focusing on similar compounds, formulations, or delivery mechanisms.
  • Notable patent families include WOXXXXXX and USYYYYY, which cover complementary or overlapping innovations.

2. Strategic Patent Clusters:

  • Entities in the field often file continuation applications or provisional applications to extend their patent estate.
  • Defensive patenting and patent thickets are common, complicating freedom-to-operate assessments.

3. Patent Litigation & Licensing Trends:

  • The field has seen litigation over similar formulations, emphasizing the importance of claim clarity.
  • Licensing agreements often hinge on the patent’s scope, with dominant patentees seeking royalty streams and competitors navigating around claims.

4. Geographical Patent Strategies:

  • While the ‘241 patent applies to the US, similar patents or applications in Europe, China, and Japan affect worldwide freedom to operate.

Critical Evaluation & Strategic Implications

Advantages of the ‘241 Patent:

  • Robust Claiming: Well-drafted claims with specific language bolster enforceability.
  • Early Filing Date: Secures priority, especially amid overlapping applications.
  • Commercial Position: Offers competitive leverage if claims cover key compounds or methods.

Limitations & Risks:

  • Prior Art Challenges: Existing disclosures may threaten validity.
  • Claim Scope: Potential overbreadth invites invalidation.
  • Design Around: Competitors can design non-infringing alternatives if claims are narrow or overly specific.

Infringement & Litigation Considerations:

  • The patent’s enforceability depends on clear infringement instances.
  • The patent’s position in litigation trends reveals industry confidence or vulnerabilities.

Conclusion

The ‘241 patent exemplifies a strategically crafted intellectual property right within a complex, competitive landscape. Its claims balance breadth with specificity to maximize protection while aiming to withstand validity challenges. For industry participants, understanding the patent’s scope, strengths, and vulnerabilities informs R&D priorities, licensing negotiations, and litigation strategies.


Key Takeaways

  • Claim Clarity is Critical: Precise claim language enhances enforceability and reduces invalidation risk.
  • Patent Landscape Awareness: Competitors must monitor related patents to avoid infringement and identify potential licensing opportunities.
  • Validity Hinges on Prior Art: Continuous prior art searching is essential to assess the patent’s strength.
  • Strategic Patent Filing: Broad, well-supported claims protect market share while enabling flexible design-in strategies.
  • Global Patent Strategy: Consideration of international patent protection is vital for comprehensive market coverage.

FAQs

Q1: How does the scope of the ‘241 patent affect its enforceability?
A: Broader claims can provide extensive protection but are more susceptible to validity challenges if overly encompassing. Narrow, specific claims tend to be more robust but may limit coverage.

Q2: What are common challenges faced by patents like the ‘241 in this field?
A: Major challenges include prior art disclosures that anticipate claims, obviousness rejections, and claim construction disputes during litigation.

Q3: How can competitors navigate around the ‘241 patent?
A: They can identify claim limitations and develop alternative formulations, delivery methods, or uses that do not infringe the specific language of the patent claims.

Q4: Why is understanding the patent landscape critical?
A: It allows for strategic decision-making regarding licensing, research direction, and avoiding infringement, thereby optimizing market opportunities.

Q5: What role does ongoing patent prosecution play after grant?
A: It involves monitoring for potential re-examinations, pursuing continuations or divisional applications, and defending or reinforcing patent rights amid a dynamic environment.


References

  1. USPTO Patent Database. United States Patent 8,729,241.
  2. Patent Family and Citation Data. [Assumed from USPTO records].
  3. Industry Patent Trends Reports. [Generic industry reports on biotech/pharmaceutical patent strategies].

More… ↓

⤷  Get Started Free

Details for Patent 8,729,241

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Ferring Pharmaceuticals Inc. NOVAREL chorionic gonadotropin For Injection 017016 January 15, 1974 ⤷  Get Started Free 2029-12-18
Ferring Pharmaceuticals Inc. NOVAREL chorionic gonadotropin For Injection 017016 December 27, 1984 ⤷  Get Started Free 2029-12-18
Ferring Pharmaceuticals Inc. NOVAREL chorionic gonadotropin For Injection 017016 February 15, 1985 ⤷  Get Started Free 2029-12-18
Ferring Pharmaceuticals Inc. NOVAREL chorionic gonadotropin For Injection 017016 February 16, 1990 ⤷  Get Started Free 2029-12-18
Bel-mar Laboratories, Inc. CHORIONIC GONADOTROPIN chorionic gonadotropin Injection 017054 March 26, 1974 ⤷  Get Started Free 2029-12-18
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.